Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Major Shareholder Ltd Chione Buys 400,000 Shares of Stock

Acrivon Therapeutics, Inc. (NASDAQ:ACRVGet Rating) major shareholder Ltd Chione purchased 400,000 shares of the business’s stock in a transaction that occurred on Thursday, November 17th. The stock was bought at an average cost of $12.50 per share, for a total transaction of $5,000,000.00. Following the acquisition, the insider now owns 3,856,597 shares in the company, valued at approximately $48,207,462.50. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Acrivon Therapeutics Stock Performance

Shares of NASDAQ ACRV opened at $12.51 on Tuesday. Acrivon Therapeutics, Inc. has a 12-month low of $12.50 and a 12-month high of $20.70.

About Acrivon Therapeutics

(Get Rating)

Acrivon Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops precision oncology medicines. The company's lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1/2 for use in the treatment of platinum-resistant ovarian cancer; endometrial and bladder cancer; and SCCs, including SCCHN, cervical, and anal cancer.

See Also

Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.